Wave Life Sciences/$WVE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Wave Life Sciences
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
- Ticker
- $WVE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 317
- Headquarters
- Cambridge, United States
- Website
- wavelifesciences.com
WVE Metrics
BasicAdvanced
$709M
-
-$1.07
-1.43
-
Price and volume
Market cap
$709M
Beta
-1.43
52-week high
$5.53
52-week low
$3.04
Average daily volume
3.2M
Financial strength
Current ratio
8.375
Quick ratio
8.085
Long term debt to equity
0.097
Total debt to equity
0.108
Profitability
EBITDA (TTM)
-224.19
Gross margin (TTM)
-189.60%
Net profit margin (TTM)
-296.86%
Operating margin (TTM)
-320.94%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-37.97%
Return on equity (TTM)
-78.80%
Valuation
Price to revenue (TTM)
9.981
Price to book
1.76
Price to tangible book (TTM)
3.53
Price to free cash flow (TTM)
-3.397
Free cash flow yield (TTM)
-29.44%
Free cash flow per share (TTM)
-1.057
Growth
Revenue change (TTM)
-35.07%
Earnings per share change (TTM)
43.60%
3-year revenue growth (CAGR)
-6.04%
10-year revenue growth (CAGR)
56.42%
3-year earnings per share growth (CAGR)
8.60%
10-year earnings per share growth (CAGR)
-6.64%
What the Analysts think about WVE
Analyst ratings (Buy, Hold, Sell) for Wave Life Sciences stock.
Analyst projections of the future price of Wave Life Sciences stock.
Bulls say / Bears say
WVE-006 produced wild-type AAT and cut harmful Z-AAT in early AATD testing, with effects maintained for at least three months after dosing and similar biomarker results on a monthly schedule. That supports a potentially convenient treatment for both lung and liver disease. (Wave Life Sciences)
The FDA has aligned with Wave on a planned WVE-006 registrational trial, including a one-year interim analysis that could support accelerated approval, and accepted the company’s assay for the programme. This gives the lead asset a clearer route towards registration, although approval is not assured. (Wave Life Sciences)
WVE-007 showed reductions in visceral and total fat while preserving muscle in early testing, and Wave has advanced it into Phase 2a monotherapy and combination trials. If those results hold in larger, higher-BMI groups, its differentiated profile could broaden its obesity opportunity. (Wave Life Sciences, Wave Life Sciences)
WVE-006 evidence remains early: the reported AAT changes come from a small, open-label Phase 1b/2a study and are biomarkers rather than demonstrated improvements in patients’ health outcomes. The planned registrational study will take two years, leaving substantial clinical and regulatory risk. (Wave Life Sciences, Wave Life Sciences)
WVE-007’s early single-dose study involved people with an average BMI of about 32, while its Phase 2a study targets people with a BMI of 35–50 and comorbidities. The effect in this more relevant, higher-risk group—and whether body-fat changes translate into meaningful weight loss—remains unproven. (Wave Life Sciences)
Wave remains loss-making, and its second-quarter net loss widened to $69.4 million from $50.5 million a year earlier as collaboration revenue fell to $2.3 million from $8.7 million. Its cash runway into the third quarter of 2028 helps, but ongoing development spending leaves execution and future funding needs as risks. (Wave Life Sciences)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
WVE Financial Performance
Revenues and expenses
WVE Earnings Performance
Company profitability
Upcoming events
No upcoming events
WVE News
AllArticlesVideos
Funds containing WVE
Fund name | Fund size | $WVE weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.